Ingalls & Snyder LLC’s Eledon Pharmaceuticals ELDN Stock Holding History

Ingalls & Snyder LLC’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$204K	Hold	51,849	–	–	0.01%	432
2026 Q1	$160K	Hold	51,849	–	–	0.01%	443
2025 Q4	$78K	Hold	51,849	–	–	﹤0.01%	458
2025 Q3	$134K	Hold	51,849	–	–	﹤0.01%	461
2025 Q2	$141K	Hold	51,849	–	–	0.01%	443
2025 Q1	$176K	Hold	51,849	–	–	0.01%	419
2024 Q4	$214K	Hold	51,849	–	–	0.01%	403
2024 Q3	$129K	Hold	51,849	–	–	0.01%	431
2024 Q2	$137K	Hold	51,849	–	–	0.01%	403
2024 Q1	$107K	Hold	51,849	–	–	﹤0.01%	425
2023 Q4	$93K	Hold	51,849	–	–	﹤0.01%	419
2023 Q3	$71K	Buy	51,849 +1,000	+2%	+$1.33K	﹤0.01%	415
2023 Q2	$70K	Hold	50,849	–	–	﹤0.01%	418
2023 Q1	$120K	Hold	50,849	–	–	0.01%	402
2022 Q4	$116K	Sell	50,849 -300	-0.6%	-$741	0.01%	413
2022 Q3	$141K	Hold	51,149	–	–	0.01%	401
2022 Q2	$125K	Hold	51,149	–	–	0.01%	420
2022 Q1	$202K	Hold	51,149	–	–	0.01%	439
2021 Q4	$226K	Hold	51,149	–	–	0.01%	428
2021 Q3	$316K	Hold	51,149	–	–	0.01%	374
2021 Q2	$405K	Hold	51,149	–	–	0.02%	342
2021 Q1	$547K	Buy	+51,149	New	+$772K	0.03%	282

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Ingalls & Snyder LLC's ELDN Position: Q2 2026 in Review

Ingalls & Snyder LLC held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 51,849 shares worth $204K. The position accounts for 0.01% of the portfolio, ranked #432.

Ingalls & Snyder LLC first reported a position in ELDN in Q1 2021 and has held it in 22 quarters since. The position peaked at $547K in Q1 2021. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Ingalls & Snyder LLC held 51,849 shares of Eledon Pharmaceuticals worth $204K as of Q2 2026.
Ingalls & Snyder LLC left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
Eledon Pharmaceuticals made up 0.01% of Ingalls & Snyder LLC's portfolio in Q2 2026, its #432 holding.
Ingalls & Snyder LLC first reported a position in Eledon Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
Ingalls & Snyder LLC's Eledon Pharmaceuticals position peaked at $547K in Q1 2021.
161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Ingalls & Snyder LLC's 13F filing for Q2 2026, filed 14 Aug 2026.